This model displayed immunotherapy response biomarkers, including tumor expression of MHC-I and PD-L1, immune cell expression of the PD-1 checkpoint, tumor cells’ responsiveness to IFNγ, high tumor mutation burden, low tumor heterogeneity, and high immune reactivity in vitro and in vivo. Here, PDCD1 is linked to neoplasm.